A 17 year old male with a history of bronchial asthma was admitted to the intensive care unit in severe respiratory distress. During a two week period of intensive respiratory care he received large doses of aminophylline and corticosteroids. In addition, pancuronium was given to facilitate ventilation and to reduce airway pressure. Large doses of pancuronium, as much as 5 mg/hr, were required to stop spontaneous respiratory efforts and restlessness. The total pancuronium dose given during the two week period was 800 rag. One hour after pancuronium was discontinued the patient could open his eyes and move his lips. Peripheral nerve stimulation indicated partial paralysis which improved promptly following a test dose of edrophonium.
AMINOPHYLLINE 1 and hydrocortisone 2 have been shown to reverse the neuromuscular blocking effect of pancuronium. The following is a case report of resistance to pancuronium in an asthmatic patient receiving large doses of aminophylline and steroids. CASE 
REPORT
The patient, a 17 years old male weighing 55 kg, had a history of bronchial asthma and multiple hospitalizations due to repeated episodes of severe wheezing and respiratory distress from the age of three years. He had been taking aminophylline and terbutaline orally and inhaling nebulized metaproteranol and belcomethasone intermittently, On arrival in the emergency room on this admission the patient was in severe respiratory distress, unresponsive, and deeply cyanotic. Respiratory rate was 38/min, blood pressure 21.3/10.6 kPa (160/80 torr), and pulse 156/rain and regular. The trachea was immedi- ately intubated and the lungs ventilated mechanically, 10 ml'kg -1 at a rate of 10 breaths/min, and the following medications were given: terbutaline 0.5 mg subcutaneously, isoetharine 2.5 ml by a nebulizer, hydrocortisone 250mg and aminophylline 500 mg both intravenously. Diazepam 40 mg and morphine 20 mg, in intermittent doses, were also given for sedation.
At first the patient's condition improved and his arterial blood gases on F~o2 0.5 were: Po2 9.57 kPa (72 torr), PCO2 5.32 kPa (40 torr), [H +] a 46.77 nmol/1 (pH 7.33). But shortly thereafter his condition deteriorated: wheezing and airway pressure increased and arterial blood gases declined (Po2 5.85 kPa (44 tort), Pco2 7.98kPa (60 torr), [H § ] a 125.89 nmol/l (pH 6.9)) and the patient became combative. A variety of bronchodilators, steroids, sedatives, and pancuronium in large doses were given during the following two weeks (see Table I ). Blood aminophylline level was maintained at 15-22 mg/ml. Pancuronium was given whenever spontaneous respiratory efforts and restlessness increased airway pressure. However, single doses of pancuronium 2 mg, freshly obtained from the operating room daily, often failed to stop spontaneous respiratory efforts and a continuous infusion of 5 mg/hr was required. Several attempts to wean the patient off the ventilator 280 
After two weeks of intensive respiratory care the patient started to show signs of improvement: the wheezing diminished, chest x-ray cleared, and the arterial blood gases on FIo20.3 were: Po~ 13.03 kPa (98 torr), Pco2 3,99 kPa (30 tort), and [H +] a 31.62 nmol/l (pH 7.50). Liver and renal function remained within normal range during his hospital stay.
On the 14th day pancuronium was discontinued. One hour later the patient could open his eyes and move his lips. However, he made no spontaneous respiratory efforts and his extremities remained limp. Electrodiagnostic studies of the neuromuscular junction indicated residual non-depolarizing blockade. A test dose of intravenous edrophonium 10 mg was followed by a dramatic improvement in muscular power. Urine, collected 24 hours after pancuronium administration had been discontinued, was analyzed and found to contain insignificant amounts of pancuronium.
The patient was gradually weaned off the ventilator and was discharged two weeks later in satisfactory condition. There was no evidence of neuromuscular compromise during that period of time.
DISCUSSION
Paneuronium is excreted primarily by the kidneys and to a lesser degree by the liver.l Twenty to fifty per cent of a single dose is excreted within 24 hours, most of it during the first 3-4 hours.I Other factors, such as drugreceptor dissociation rate and muscle perfusion, also determine the rate of recovery of the neuromuscular junction. 2 We have no reason to believe that any of these factors operated abnormally in our patient, except for the possible effect of the beta adrenergic agents, terbutaline and isoetharine, on muscle perfusion. Beta adrenergic agents are known for their potent dilatory effect on arterioles of skeletal muscles 3 and they could possibly facilitated the recovery of our patient from pancuronium.
In addition to the large doses of pancuronium, our patient also received large doses of aminophylline and corticosteroids, which are known for their interaction with muscle relaxants. Aminophylline antagonizes non-depolarizing muscle relaxants in the cat 4 and in man. s It is speculated that the mechanism of the aminophylline-induced resistance to muscle relaxants is based on the ability of aminophylline to inhibit the enzyme phosphodiesterase at the pre-junctional membrane of the neuromuscular junction, as do all theophyllines, and thus it increases c-AMP level. The high c-AMP level promotes acetylcholine release, which in turn antagonizes the blocking effect of non-depolarizing muscle relaxants.
Corticosteroids also have been shown to facilitate neuromuscular transmission. Hydrocortisone has been reported to reverse pancuronium-induced paralysis in an hypophysectomized patient. 7 Although the mechanism is not completely clear, corticosteroids antagonize the blocking effect of hemicholinium-3 at the neuromuscular junction, possibly by facilitating choline transport at the pre-junctional membrane, s This could also possibly be tiae mechanism of corticoid-induced reversal of pancuronium.
In summary, we feel that this patient exhibited resistance to pancuronium due to the antagonizing effect of aminophylline, and perhaps also of corticosteroids. Monitoring the neuromuscular junction with a nerve stimulator and titrating the dose of the muscle relaxant accordingly would improve the management of asthmtic patients in acute respiratory failure.
